Skip to main content

It looks like you are visiting from outside the EU. Switch to the US version to see local pricing in USD and local shipping.

Switch to US ($)

🚀 Special Offer🚀Get 25% off on your bioreagent online order (except Micelles and Nanodiscs), with the code: PROTEOSHOP25

📢 New ! Accelerate your Antibody Development with Ready-to-use Stable Cell Pools

Explore Now
  • Wide range of unique reagents
  • Free Shipping
    Free shipping in EU on Orders > €500
  • Fast worldwide delivery
    Fast worldwide delivery

Anti-Hu CD38 PE-Cy (TM)7

Reference: T7-366-T100
Size

100T

Isotype

IgG1

Brand

Exbio

Host Species

Mouse

Clonality

Monoclonal Antibody

Product nameAnti-Hu CD38 PE-Cy (TM)7
Delivery conditionBlue ice (+4°C)
Delivery lead time in business days3-5 days if in stock; 3-5 weeks if production needed
Storage conditionStore at 2-8°C. Protect from prolonged exposure to light. Do not freeze.
BrandExBio
Host speciesMouse
IsotypeIgG1
ClonalityMonoclonal Antibody
ImmunogenHuman thymocytes in foetus
Clone NameHIT2
Protein NameCD38
FormatLiquid in stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Description of Anti-Hu CD38 PE-Cy (TM)7

The mouse monoclonal antibody HIT2 reacts with an extracellular epitope of CD38, a 45 kDa type II transmembrane glycoprotein strongly expressed mainly on plasma cells and activated T and B lymphocytes; it is an antigenic marker of lymphoid cells. Its binding is blocked by daratumumab.

CD38 (NAD+ glycohydrolase) is a type II transmembrane glycoprotein able to induce activation, proliferation and differentiation of mature lymphocytes and mediate apoptosis of myeloid and lymphoid progenitor cells. Another role of CD38 is provided by enzymatic activity of its extracellular part. CD38 acts as NAD+ glycohydrolase converting NAD+ into ADP-ribose, as ADP-ribosyl cyclase producing cADPR and as cADPR hydrolase, thus affecting levels of calcium-mobilizing metabolites. ADPR produced by CD38 serves as an important second messenger of neutrophil and dendritic cell migration. CD38 belongs to markers of B cell subsets, leukemia, and a target of immunotherapy in myeloma treatment.

Flow cytometry: The reagent is designed for analysis of human blood cells using 4 μl reagent / 100 μl of whole blood or 106 cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.

Publication

  • Leukocyte Typing III., McMichael AJ et al (Eds.), Oxford University Press (1987).
  • Rozková D, Novotná L, Pytlík R, Hochová I, Kozák T, Bartůnková J, Spísek R: Toll-like receptors on B-CLL cells: expression and functional consequences of their stimulation. Int J Cancer. 2010 Mar 1;126(5):1132-43., URL: https://www.ncbi.nlm.nih.gov/pubmed/19685493
  • Kolar GR, Mehta D, Pelayo R, Capra JD: A novel human B cell subpopulation representing the initial germinal center population to express AID. Blood. 2007 Mar 15;109(6):2545-52., URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1852199/
  • Všianská P, Říhová L, Varmužová T, Suská R, Kryukov F, Mikulášová A, Kupská R, Penka M, Pour L, Adam Z, Hájek R: Analysis of B-cell subpopulations in monoclonal gammopathies. Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):e61-71., URL: http://www.ncbi.nlm.nih.gov/pubmed/25578543
  • Ratuszny D, Skripuletz T, Wegner F, Groß M, Falk C, Jacobs R, Ruschulte H, Stangel M, Sühs KW: Case report: Daratumumab in a patient with severe refractory anti-NMDA receptor encephalitis. Front Neurol. 2020 Dec 22;11:602102., URL: https://pubmed.ncbi.nlm.nih.gov/33414761/
  • Pape LJ, Hambach J, Gebhardt AJ, Rissiek B, Stähler T, Tode N, Khan C, Weisel K, Adam G, Koch-Nolte F, Bannas P: CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy. Front Immunol. 2022 Oct 27:13:1010270., URL: https://pubmed.ncbi.nlm.nih.gov/36389758/
  • Taussig DC, Miraki-Moud F, Anjos-Afonso F, Pearce DJ, Allen K, Ridler C, Lillington D, Oakervee H, Cavenagh J, Agrawal SG, Lister TA, Gribben JG, Bonnet D: Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 2008 Aug 1;112(3):568-75., URL: https://pubmed.ncbi.nlm.nih.gov/18523148/
  • Ruiz-Lorente I, Gimeno L, López-Abad A, López Cubillana P, Fernández Aparicio T, Asensio Egea LJ, Moreno Avilés J, Doñate Iñiguez G, Guzmán Martínez-Valls PL, Server G, Ferri B, Campillo JA, Martínez-Sánchez MV, Minguela A: Differential role of NKG2A/HLA-E interaction in the outcomes of bladder cancer patients treated with M. bovis BCG or other therapies. Biomedicines 2025 Jan 10;13(1):156., URL: https://pubmed.ncbi.nlm.nih.gov/39857739/
  • Kužílková D, Puñet-Ortiz J, Aui PM, Fernández J, Fišer K, Engel P, van Zelm MC, Kalina T: Standardization of workflow and flow cytometry panels for quantitative expression profiling of surface antigens on blood leukocyte subsets: An HCDM CDMaps initiative. Front Immunol. 2022 Feb 11:13:827898. , URL:

    Reviews

    There are no reviews yet.

    REVIEW YOUR PRODUCT

    Be the first to review “Anti-Hu CD38 PE-Cy (TM)7”

    Your email address will not be published. Required fields are marked *

Contact us

Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.

    Cart (0 Items)

    Your cart is currently empty.

    View Products